Category REGENERATIVE MEDICINE

PIER MARIA FORNASARI
2021-04-30

Extracellular Vesicles from Human Adipose-Derived Mesenchymal Stem Cells: A Review of Common Cargos published in Stem Cell Reviews and Reports

In recent years, the interest in adipose tissue mesenchymal cell–derived extracellular vesicles (AT-MSC-EVs) has increasingly grown. Numerous articles support the potential of human AT-MSC-EVs as a new therapeutic option for treatment of diverse diseases in the musculoskeletal and cardiovascular systems, kidney, skin, and immune system, among others. This approach makes use of the molecules transported

Read More

No Comments InCELL THERAPY
PIER MARIA FORNASARI
2021-04-22

Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): an international, multicentre, observational cohort study published on The Lancet Haematology

Chimeric antigen receptor (CAR) T-cell therapy can induce side-effects such as cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome (ICANS), which often require intensive care unit admission. The aim of the study, published in The Lancet Haematology was to describe management of critically ill CAR T-cell recipients in intensive care. An international, multicentre, observational

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-04-15

Risdiplam improves motor function and survival in infants with SMA

PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial of Evrysdi (risdiplam), which demonstrated that infants with type 1 spinal muscular atrophy (SMA) continued to show improvements in survival and key motor milestones after two years of treatment. PTC Therapeutics has reported results from Part 2 of the pivotal FIREFISH trial

Read More

No Comments InADVANCED THERAPY MEDICINAL PRODUCT
PIER MARIA FORNASARI
2021-04-04

First FDA approval of CAR T-cell therapy for multiple myeloma marks milestone for patients

Approval of ide-cel for adults who have relapsed after four or more prior lines of therapy follows clinical trials led by Dana-Farber Cancer Institute investigators The Food and Drug Administration (FDA) has granted its first approval of a CAR T-cell therapy for adults with multiple myeloma, bringing welcome hope for patients eligible for the treatment, according to researchers

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-03-23

Gene therapy using “zinc fingers” may help treat Alzheimer’s disease, animal study shows

Key Takeaways A single injection of a gene therapy involving what are called zinc fingers dramatically reduced levels of tau, a protein implicated in Alzheimer’s disease, in mice with the condition. The treatment was long lasting, caused no side effects, and reduced Alzheimer’s-related damage in the brain. The technology worked just the way we had

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2021-03-23

Retroviral gene therapy with a view on previous experience and future perspectives

Gene therapy can be used to restore cell function in monogenic disorders or to endow cells with new capabilities, such as improved killing of cancer cells, expression of suicide genes for controlled elimination of cell populations, or protection against chemotherapy or viral infection. While gene therapies were originally most often used to treat monogenic diseases

Read More

No Comments InGENE THERAPY RARE DISEASES
PIER MARIA FORNASARI
2021-03-23

Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

Chimeric antigen receptor (CAR)-T cell therapies are on the verge of becoming powerful immunotherapeutic tools forcombating hematological diseases confronted with pressing medical needs. Lately, CAR-NK cell therapies have also come into focus as novel therapeutic options to address hurdles related to CAR-T cell therapies, such as therapy-induced side effects. Currently, more than 500 CAR-T and

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-03-19

A leap for­ward in research on CAR T cell ther­apy – Cel­lu­lar en­gin­eer­ing makes it pos­sible to tar­get the ther­apy also against solid tu­mours

A study recently published in the journal Science looked into how CAR T immunotherapy could be used to treat solid tumours in addition to leukaemias. The programming of CAR T cells opens avenues for applying cell therapies to, for example, breast cancer or ovarian cancer in the future. In cancer immunotherapy, cells in the patient’s

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-03-08

The challenges of CAR T-cell therapy for pediatric B-ALL. RESTORE launched Fragments of Life: A success in the frontier of medicine becomes a video game.

Sara Ghorashian, PhD, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK, outlines the challenges associated with CAR T-cell therapy for pediatric B-cell acute lymphoblastic leukemia (ALL). Discovering the best treatment phasing with other immunotherapies, such as blinatumomab and inotuzumab, improving the toxicity profile, and CAR T-cell persistence are some of the remaining

Read More

No Comments InCAR-T
PIER MARIA FORNASARI
2021-02-24

Chimeric antigen receptor T-cell therapy in multiple myeloma: a systematic review and meta-analysis of 950 patients

Despite dramatic improvements in survival, multiple myeloma (MM) remains largely incurable, and most patients develop disease that is refractory to available treatment options. A paper just published on Blood Advances by researchers of Department of Hematological Malignancies and Cellular Therapeutics, Kansas University Medical Center, Westwood, Division of Gastroenterology, University of Toledo, Division of Hematology and

Read More

No Comments InCAR-T